In contrast, amyloid-PET change rates were not linked to cognitive changes.<h4>Discussion</h4>Plasma p-tau<sub>217</sub> offers a cost-effective AD-specific alternative to tau-PET and could potentially be implemented for monitoring cognitive changes in AD trials, while amyloid-PET lacks utility. This evidence concerns the gene MAPT and Alzheimer disease.